Eli Lilly’s stock (NYSE: LLY) continues its relentless ascent, solidifying its position as a titan not just in pharmaceuticals, but within the broader market narrative of growth and innovation. Trading back above $900 at $918 as of pre-market, LLY has added 2.12% in the session, to the 1.52% gain seen yesterday. With earnings due before market open, we take a closer look at what to expect from the print.

Consensus estimates for the upcoming Q1 2025 report point to EPS of $3.26 on revenue of $12.67B. Full-year 2025 projections are even more bullish, forecasting EPS of $22.40 (a 72.44% YoY leap) and revenue of $59.49B (up 32.08%). Indeed, Lilly itself raised its 2025 revenue guidance significantly to $58–$61 billion,…